vicriviroc

The Top 10 Phase III Failures of 2010
Fierce Biotech
Fri, 10/22/10 - 11:36 am
clinical trials
dimebon
Medivation
Pfizer
ocrelizumab
Roche
rheumatoid arthritis
taspoglutide
diabetes
Ipsen
semagacestat
Eli Lilly
ASA404
Antisoma
Novartis
Novelos Therapeutics
AstraZeneca
zibotentan
vicriviroc
Merck
Recentin
Vical
Sanofi
Setback for Merck
Yahoo/Zacks.com
Thu, 01/21/10 - 10:24 am
Merck
Gilead Sciences
Pfizer
JNJ
vicriviroc
HIV